Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Recurrent Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer · Recurrent Endometrial Cancer · Endometrial Cancer · Low-grade Serous Ovarian Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 890 (planned)
- Started
- May 21, 2018
- Main results expected
- May 10, 2027
- Fully finished
- May 10, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapy
Measured over: From Cycle 1, Day 1 up to 35 days
Number of participants with DLTs for ubamatamab with cemiplimab
Measured over: From Cycle 2, Day 1 up to 21 days
Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for ubamatamab monotherapy
Measured over: Up to 2 years
Number of participants with TEAEs (including imAEs) for ubamatamab with cemiplimab
Measured over: Up to 2 years
Number of participants with serious adverse events (SAEs) for ubamatamab monotherapy
Measured over: Up to 2 years
Number of participants with SAEs for ubamatamab with cemiplimab
Measured over: Up to 2 years
Number of deaths for ubamatamab monotherapy
Measured over: Up to 2 years
Number of deaths for ubamatamab with cemiplimab
Measured over: Up to 2 years
Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for ubamatamab monotherapy
Measured over: Up to 2 years
Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for ubamatamab with cemiplimab
Measured over: Up to 2 years
Concentration of ubamatamab in serum over time for ubamatamab monotherapy
Measured over: Up to 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03564340 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC